Pentagon developing protective bubble for Ebola patients; Creo gets $5.5M for electrosurgical system;

@FierceMedDev: Congress considering bill to limit FDA regulation of EHRs, clinical decision support software. Story | Follow @FierceMedDev

@VarunSaxena2: RT @FierceMedDev: From FierceDrugDelivery: Survey raises the question: Do patients really know how to use drug delivery devices? Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: LabCorp and CareDx call it quits on partnership to develop lupus test. FierceDiagnostics story | Follow @EmilyWFierce

> Innovative Cardiovascular Solutions raised $5 million towards its Emblok Embolic Protection Catheter for heart interventional procedures. Release

> The Pentagon is working on development of a "care cube" that will act as a protective bubble allowing medics to assist Ebola patients with lower risk of infection. Story

> Ireland's Neuromod Devices received a CE mark for Mutebutton, its multi-sensory medical device used to treat tinnitus. Read

> Device developer Creo Medical closed a £3.5 million ($5.5 million) funding round to use towards continuing development of the CROMA platform, an electrosurgical system. Release

Biotech News

@FierceBiotech: Woodford's investment strategy may help change the global biotech scene. Editor's Corner | Follow @FierceBiotech

@JohnCFierce: Fledgling biotech upstart blends cutting-edge cancer immunotherapy strategies -- BeneVir. Article | Follow @JohnCFierce

@DamianFierce: It's almost as if Italian authorities don't care about biotech traders. More | Follow @DamianFierce

> Amgen, AstraZeneca's brodalumab beats J&J's Stelara in 2nd PhIII psoriasis showdown. News

> Biotech's Boston blitz is making lab space harder--and costlier--to come by. Story

> Novartis cans a researcher whose cooked data led to a slew of retractions. More

Pharma News

@FiercePharma: Merck KGaA to power India plant with coconut and cashew shells. Story | Follow @FiercePharma

@CarlyHFierce: AstraZeneca's Almirall buy yields its first new drug--and now, AZ has to sell it. More | Follow @CarlyHFierce

> Who are the stars of personalized meds? Roche, Novartis and J&J. More

> Sanofi's pre-game show on Afrezza has MannKind followers chattering. Item

> Odds for a Pfizer-AZ matchup? All over the map, if you listen to analysts. Article

Drug Delivery News

> RNAi specialist Arrowhead reports loss of $58.7M in FY 2014. Item

> Singapore team combines cancer drugs, diagnostics in one biomarker nanoparticle. Report

> 'Hybrid' delivery vehicle gives DNA vaccines new potential. News

> Survey raises the question: Do patients really know how to use drug delivery devices? More

> Patients respond positively to Cynapsus film strip of apomorphine to combat Parkinson's. Article

Diagnostics News

> Curetis nabs $18M to support European Dx rollout, U.S. trial, possible IPO. News

> Illumina and bioMérieux to develop innovative sequencing system for infectious diseases. Article

> Indian startup develops low-cost, portable Dx for developing countries. Story

> LabCorp and CareDx call it quits on partnership to develop lupus test. Report

> Illumina teams up with Broad Institute, USAID for Ebola tracking. Item

Pharma Marketing News

> Who are the stars of personalized medicine? Roche, Novartis and J&J. Article

> From GPS inhalers to Jawbone data-gathering, some digital pharma inspiration. Story

> MannKind fans and critics line up for Sanofi's Afrezza pre-game show. More

> Ipsen on a hiring binge in U.S. to prep for new Somatuline marketing push. Story

> AstraZeneca's Almirall buy yields its first new drug--and now, AZ has to sell it. Article

Suggested Articles

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.

Akoya Biosciences raised $50 million to help boost its commercialization in research, drug development and clinical testing markets.